Preclinical development and multimodal imaging of novel immunovirotherapeutics for cancer (C07)

点击翻译按钮获取中文摘要

Oncolytic viruses represent a novel class of cancer therapeutics, due to their intrinsic ability to selectively lyse infected tumor cells, while priming potent anti-tumor immune responses to provide lasting systemic immunity. We propose the combination of a novel pseudotyped vesicular stomatitis virus vector with adoptive T cell therapy as a powerful viro-immunotherapeutic strategy. We will employ multimodal and multiparametric imaging to noninvasively monitor the biodistribution and kinetics of the therapeutic agents, as well as to image specific biological changes to the local microenvironment in response to the therapy, in order to facilitate clinical translation and identify predictive biomarkers of response.